Dec 21: Hyderabad-based bio pharma major Suven Life Sciences Ltd on Thursday announced that the grant of one product patent from Canada (2932428) and one product patent from India (289123) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034 and 2028 respectively.
The granted claims of the patents include the class of selective 5-HT4 and 5-HT6 compounds respectively and are being developed as therapeutic agents for major depressive disorders and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia respectively.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.
Shares of the company rose up to 191.50 from the previous closing of Rs 188.25 on BSE in morning trade after the news came in. At 11.16 am, the Re 1 face value shares were trading at Rs 188.50, up 0.13% from the previous close.